These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30783329)

  • 21. Eruptive palmoplantar lesions induced by capecitabine: report of a case evaluated with dermoscopy.
    García-Lozano JA; Ocampo-Candiani J; González-Ramírez RA
    Cir Cir; 2019; 87(S1):38-42. PubMed ID: 31501632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of palmoplantar dysesthesia syndrome caused by capecitabine].
    Elmas ÖF; Metin MS; Kızılyel O; Aktaş A; Birdal C
    Agri; 2016 Jan; 28(1):54-6. PubMed ID: 27225615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of dermatomyositis triggered by tegafur.
    Akiyama C; Osada A; Sou K; Yasaka N; Ohtake N; Furue M; Tamaki K
    Acta Derm Venereol; 1997 Nov; 77(6):490. PubMed ID: 9394998
    [No Abstract]   [Full Text] [Related]  

  • 24. A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma.
    Kara A; Alatas E; Dogan G; Celik SY; Tanriverdi O
    J Oncol Pharm Pract; 2016 Oct; 22(5):717-9. PubMed ID: 25994157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rechallenging 5-Fluorouracil in a Patient With Capecitabine-Induced Ventricular Fibrillation.
    Lai S; Marshall JL; Morrissey RL
    Clin Colorectal Cancer; 2015 Sep; 14(3):198-201. PubMed ID: 25858685
    [No Abstract]   [Full Text] [Related]  

  • 26. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
    Kodali S; Bathini V; Rava P; Tipirneni E
    J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
    [No Abstract]   [Full Text] [Related]  

  • 28. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy.
    Li Z; Jiang N; Xu Y
    Australas J Dermatol; 2016 Feb; 57(1):e14-6. PubMed ID: 25495707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
    Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE;
    Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine-Induced Takotsubo Cardiomyopathy: A Case Report and Literature Review.
    Qasem A; Bin Abdulhak AA; Aly A; Moormeier J
    Am J Ther; 2016; 23(5):e1188-92. PubMed ID: 25549075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
    Sauter C; Saborowski A; Ockenfels HM
    Hautarzt; 2007 Jul; 58(7):619-22. PubMed ID: 17066280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Permanent lesion to the corticospinal tract after therapy with capecitabine.
    Wagner-Altendorf TA; Heldmann M; Hanssen H; Münte TF
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
    Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capecitabine-induced eruptive acral hyperpigmentation: Clinical and dermoscopic evaluation of two cases.
    Peccerillo F; Pampena R; Giannetti L; Pellacani G; Longo C
    Dermatol Ther; 2019 May; 32(3):e12853. PubMed ID: 30748073
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
    Chan HY; Ng CM; Tiu SC; Chan AO; Shek CC
    Hong Kong Med J; 2012 Dec; 18(6):526-9. PubMed ID: 23223655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
    Ruiz-Pinto S; Pita G; Martín M; Nuñez-Torres R; Cuadrado A; Shahbazi MN; Caronia D; Kojic A; Moreno LT; de la Torre-Montero JC; Lozano M; López-Fernández LA; Ribelles N; García-Saenz JA; Alba E; Milne RL; Losada A; Pérez-Moreno M; Benítez J; González-Neira A
    Clin Pharmacol Ther; 2021 Feb; 109(2):462-470. PubMed ID: 32757270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 40. Successful Capecitabine Desensitization for a Delayed-Type Hypersensitivity Reaction.
    Demir S; Olgac M; Saglam S; Gelincik A; Colakoglu B; Buyukozturk S
    J Investig Allergol Clin Immunol; 2016; 26(1):66-7. PubMed ID: 27012024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.